RICHMOND, Va., Dec 07, 2006 (BUSINESS WIRE) -- Insmed, Inc. (NASDAQ:INSM) announced today that it will hold a conference call on Thursday, December 7 to discuss the outcome of the trial in the case of Genentech & Tercica v. Insmed. Insmed, the defendant in the patent infringement suit, will discuss the jury verdict which was returned on Wednesday, December 6.
Among participants on the call will be Geoffrey Allan, president and CEO of Insmed and Philip Young, executive vice president and CBO.
Interested investors can listen to the call over the internet from Insmed's investor relations website at www.insmed.com or by dialling 866-316-1363 (domestic) or 913-312-1233 (international).
A telephonic replay of the call will be available for one week at 888-203-1112 (domestic) or 719-457-0820 (international), pass code: 8482189. A web replay of the call will be available through the corporate website beginning at 6:00 p.m.
Insmed is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com. The company's leading product, IPLEX(TM), was approved as an orphan drug by the United States Food and Drug Administration in December 2005 for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.